Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/28/2024 | $120.00 | Underweight | Wells Fargo |
1/4/2024 | $100.00 → $125.00 | In-line → Outperform | Evercore ISI |
Wells Fargo initiated coverage of Mesa Laboratories with a rating of Underweight and set a new price target of $120.00
Evercore ISI upgraded Mesa Laboratories from In-line to Outperform and set a new price target of $125.00 from $100.00 previously
LAKEWOOD, Colo., May 28, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter ("4Q25") and full fiscal year ("FY25") ended March 31, 2025 (amounts in thousands). Fourth quarter FY25 compared to fourth quarter FY24: Revenues increased 5.5%Non-GAAP core organic revenues growth1 was 6.3%Operating income increased 100.5% to $1,469Non-GAAP adjusted operating income ("AOI") excluding unusual items2 decreased 18.0% and was 19.7% as a percentage of revenues Full FY25 compared to full FY24:
LAKEWOOD, Colo., April 07, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase p
LAKEWOOD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter ("3Q25") ended December 31, 2024 (amounts in thousands). Third quarter FY 2025 compared to third quarter FY 2024: Revenues increased 17.5%Non-GAAP core organic revenues1 increase was 13.2%Operating income increased 8,725% to $5,779Non-GAAP adjusted operating income excluding unusual items2 increased 13.3% and was 23.5% as a percentage of revenues We operate our business in four divisions: Sterilization and Disinfection Control ("SDC"
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
10-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)